NATICK, Mass., May 21, 2014 /PRNewswire/ -- Boston Scientific Corporation reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the SYNERGY ...
NATICK, Mass., Nov. 30, 2012 /PRNewswire/ -- The first patient has been enrolled in the Boston Scientific Corporation (NYSE: BSX) EVOLVE II clinical trial, which is designed to further assess the ...
JACKSONVILLE, Fla. (Ivanhoe Newswire)— It’s a good time of year to focus on our hearts, not just because it’s Valentine’s Day, but because it’s American Heart Month. Coronary heart disease, where ...
Boston Scientific's ($BSX) Synergy bioabsorbable polymer drug-eluting stent is on track for FDA approval after the successful Evolve II pivotal clinical trial ...
FARMINGTON — In an area where heart disease is the second-most common cause of death, finding ways to prevent heart attacks is one of the focuses of the San Juan Regional Medical Center's cardiology ...
Boston Scientific ($BSX) said during its Q3 earnings call that it is going to charge a premium for its Synergy drug-eluting stent in the U.S., as it seeks to ...
Boston Scientific's "blockbuster" Synergy stent for opening blocked arteries on the heart commands a higher price than its competitors, but so far the jury is out on whether it can prevent long-term ...
The idea of a permanent metallic implant being left in the coronary artery after a stent has been used to force it open following blockage has prompted many companies to look for solutions. We have ...
JACKSONVILLE, Fla. (Ivanhoe Newswire)— It’s a good time of year to focus on our hearts, not just because it’s Valentine’s Day, but because it’s American Heart Month. Coronary heart disease, where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback